Correction: The society for immunotherapy of cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
Main Authors: | Marka Crittenden, Brendan Curti, Walter J Urba, Roxanne Payne, Steven K Seung, Christopher B Fountain, ShuChing Chang, Jessica Fleser, Kimberly Phillips, Ian Malkasian, Lyn B Dobrunick |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-06-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Online Access: | https://jitc.bmj.com/content/8/1/e000155corr1.full |
Similar Items
-
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
by: Ignacio I Wistuba, et al.
Published: (2020-06-01) -
Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma
by: Walter J Urba, et al.
Published: (2020-05-01) -
Evaluation of Immunohistochemistry (IHC) in Children with Chronic Constipation
by: Amir Masood Azizpoor, et al.
Published: (2015-10-01) -
EVALUATION OF IMMUNOHISTOCHEMISTRY (IHC) MARKER HER2 IN BREAST CANCER
by: Prasanna G. Shete, et al.
Published: (2016-08-01) -
Overview of Multiplex Immunohistochemistry and Immunofluorescence Techniques
in the Lung Cancer Immunotherapy
by: Wenjia SUN, et al.
Published: (2021-01-01)